Loading...
XNAS
TNDM
Market cap1.06bUSD
Jul 25, Last price  
15.89USD
1D
2.91%
1Q
-12.02%
Jan 2017
-26.09%
IPO
-27.24%
Name

Tandem Diabetes Care Inc

Chart & Performance

D1W1MN
P/E
P/S
1.13
EPS
Div Yield, %
Shrs. gr., 5y
2.27%
Rev. gr., 5y
21.01%
Revenues
940m
+25.74%
02,474,69829,006,63849,722,00072,850,00084,248,000107,601,000183,866,000362,305,000498,830,000702,799,000801,217,000747,718,000940,203,000
Net income
-96m
L-56.86%
-25,509,824-33,015,085-63,138,849-79,524,000-72,418,000-83,447,000-73,033,000-122,611,000-24,753,000-34,382,00015,566,000-94,594,000-222,611,000-96,025,000
CFO
24m
P
-21,546,786-33,471,166-47,756,651-61,378,000-58,764,000-61,173,000-66,136,000-8,319,00041,905,00024,669,000111,359,00050,464,000-31,810,00024,225,000
Earnings
Jul 30, 2025

Profile

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
IPO date
Nov 13, 2013
Employees
2,600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
940,203
25.74%
747,718
-6.68%
801,217
14.00%
Cost of revenue
649,506
549,695
527,345
Unusual Expense (Income)
NOPBT
290,697
198,023
273,872
NOPBT Margin
30.92%
26.48%
34.18%
Operating Taxes
4,155
2,357
1,742
Tax Rate
1.43%
1.19%
0.64%
NOPAT
286,542
195,666
272,130
Net income
(96,025)
-56.86%
(222,611)
135.33%
(94,594)
-707.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
(30,000)
4,184
17,469
BB yield
1.27%
-0.22%
-0.61%
Debt
Debt current
18,208
34,120
13,121
Long-term debt
579,986
529,239
543,401
Deferred revenue
13,331
16,874
Other long-term liabilities
2,154
31,830
23,918
Net debt
85,320
95,447
(68,679)
Cash flow
Cash from operating activities
24,225
(31,810)
50,464
CAPEX
(19,231)
(26,804)
(42,952)
Cash from investing activities
(23,482)
(85,740)
33,168
Cash from financing activities
8,367
4,113
16,877
FCF
349,037
172,478
155,067
Balance
Cash
438,329
467,912
616,901
Long term investments
74,545
8,300
Excess cash
465,864
430,526
585,140
Stockholders' equity
(1,049,706)
(950,365)
(730,941)
Invested Capital
1,788,523
1,741,885
1,631,557
ROIC
16.23%
11.60%
17.75%
ROCE
39.35%
25.02%
30.41%
EV
Common stock shares outstanding
65,451
64,969
64,146
Price
36.02
21.77%
29.58
-34.19%
44.95
-70.14%
Market cap
2,357,545
22.67%
1,921,783
-33.35%
2,883,363
-70.23%
EV
2,442,865
2,017,230
2,814,684
EBITDA
304,983
213,738
288,202
EV/EBITDA
8.01
9.44
9.77
Interest
5,509
9,882
4,313
Interest/NOPBT
1.90%
4.99%
1.57%